AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toe spread out
Description: In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toe spread out
Description: In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short foot
Description: While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short foot
Description: While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heel rise
Description: After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel rise
Description: After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Towel toe curl
Description: Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Towel toe curl
Description: Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastrocnemius active static stretching exercise
Description: The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastrocnemius active static stretching exercise
Description: The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plantar fascia and gastrocnemius stretching exercise on step
Description: The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
Study NCT05000398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar fascia and gastrocnemius stretching exercise on step
Description: The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
Study NCT05493202 — intervention group
Intervention type: DEVICE
Intervention: Mira Fertility Tracker
Description: Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
Study NCT06220214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CEDM
Description: Contrast Enhanced Digital Mammography
Study NCT06220214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CEDBT
Description: Contrast-Enhanced Digital Breast Tomosynthesis
Study NCT06220214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 350mgI/mL Solution for Injection
Description: Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
Study NCT05314634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: concurrent exercise
Description: Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
Study NCT05314634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
Study NCT05868902 — intervention group
Intervention type: DEVICE
Intervention: CardioFlux Magnetocardiography
Description: The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
Study NCT04696120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid
Study NCT04696120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients who are assigned to placebo group will receive placebo
Study NCT05976087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensoExo
Description: combination of sensory feedback and the use of soft exoskeleton
Study NCT06378229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
Study NCT05642351 — intervention group
Intervention type: OTHER
Intervention: Autobiographical reminder
Description: The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~* 6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~* 5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~* 4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~* 3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~* 2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~* 1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)
Study NCT04715243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Description: High flow nasal cannula as a form of non-invasive oxygen delivery
Study NCT04715243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet NIV
Description: NIV interface
Study NCT05243823 — intervention group
Intervention type: DRUG
Intervention: Vagifem®
Description: According to local clinical practice - independent of inclusion in this study
Study NCT05243823 — intervention group
Intervention type: DRUG
Intervention: Non-Vagifem® LDVE, Estradiol
Description: According to local clinical practice - independent of inclusion in this study
Study NCT04615949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol, pharmaceutically produced with < 5 ppm THC
Description: CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Study NCT04615949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Study NCT05528705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC
Description: Subacromial spatial administration
Study NCT05528705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Description: Subacromial spatial administration
Study NCT06549478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06549478 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo BgRT
Study NCT06549478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06549478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05635656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital symptom mapping and biofeedback treatment
Description: Digital symptom mapping and biofeedback treatment
Study NCT05363553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula based on whole goat milk
Description: Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
Study NCT05363553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: infant formula based on cow milk proteins
Description: Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
Study NCT05346120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic marrow stromal cells (MSCs)
Description: stem cell infusion
Study NCT05346120 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: allogeneic marrow stromal cells (MSCs)
Description: stem cell infusion
Study NCT04715243 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Face-mask NIV
Description: NIV interface
Study NCT06413576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: homocysteine measurement
Description: measuring the serum level of homocysteine
Study NCT04337177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-413
Description: a flavored preparation of orally administered irinotecan
Study NCT04337177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: alkylating oral chemotherapy agent used to treatment brain cancers
Study NCT05222984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT05222984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO
Study NCT05222984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05351944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy skills for the intervention experimental group A
Description: Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.
Study NCT05351944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation or Atomoxetine or stimulants according to ADHD severity
Description: the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
Study NCT05941793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS-COV
Description: MBS-COV for inhalation
Study NCT05941793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for inhalation
Study NCT04890652 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital intervention
Description: All participants will receive a digital intervention designed to reduce stress and alcohol consumption over a 4-week period. The intervention will include two weekly sessions that integrate alcohol intervention with breathing-based stress management techniques.
Study NCT04696380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will sample high vs low nicotine.
Study NCT05924633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement containing a protein hydrolysate + beta glucan (Wellmune®)
Description: Supplement taken daily for 4 weeks.
Study NCT05924633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement containing maltodextron
Description: Placebo supplement taken daily for 4 weeks.
Study NCT05389293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.
Study NCT05389293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: In Cohort 2, zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR
Study NCT05840198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery & Care Canine-Assisted Therapy
Description: Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
Study NCT05840198 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Youth in this condition receive treatment as usual from their health care providers
Study NCT06479343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Embolic System (Tonbridge)
Description: Endovascular treatment with Liquid Embolic System (Tonbridge).
Study NCT06479343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Onyx Liquid Embolic System (Medtronic)
Description: Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
Study NCT05174247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFRct analysis
Description: Software analysis of Cardiac CT to show extent of pericardial stenoses
Study NCT06174246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain self-management program
Description: Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/
Study NCT06174246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management program
Description: Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/
Study NCT06174246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional support for self-management program
Description: This intervention is designed to give extra support to patients completing the online pain education program. It consists of two visits with a physiotherapist, and one group session led by a peer living with chronic musculoskeletal pain.~Sessions with the physiotherapist will occur at the beginning of the program and at the midway point. They will be used first to present the objectives and the components of the self-management program, to reinforce its potential to improve the participant's ability to manage their pain, and then to answer the participant's questions on the program and follow up on the regular completion of the lessons.~The group session will be co-facilitated by a physiotherapist and a patient-partner, and will include participants who have completed at least six weeks of the program. It will serve as a discussion forum to share helpful pain self-management strategies, lived experiences with pain and facilitators in completing the program.
Study NCT06271408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution
Description: Aerosolized albuterol
Study NCT06271408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer
Description: A vibrating mesh nebulizer will be used to deliver aerosolized albuterol
Study NCT06271408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler
Description: A metered dose inhaler will be used to deliver aerosolized albuterol
Study NCT06271408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer
Description: A jet nebulizer will be used to deliver aerosolized albuterol
Study NCT05361551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver ablation
Description: Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
Study NCT05552027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCS System- Prototype
Description: Participants will be exposed to each of the 3 scenarios with the sensor system enabled (with feedback)
Study NCT05552027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CCS System- Control
Description: The participants will be exposed to each of the 3 scenarios with the system disabled (no feedback).